Roivant Sciences (ROIV) Income from Discontinued Operations (2023 - 2024)
Roivant Sciences' (ROIV) quarterly Income from Discontinued Operations came in at 862000.0 in Q4 2024, down 122.07% YoY from 3905000.0 in Q1 2024, and down 207.21% on a QoQ basis from 804000.0 in Q3 2024.
Powered by 
Analysis
Roivant Sciences (ROIV) Income from Discontinued Operations (2023 - 2024) Analysis & Trends
Roivant Sciences (ROIV) has 2 years of Income from Discontinued Operations data on file, last reported at 862000.0 in Q4 2024.
- Quarterly Income from Discontinued Operations fell 122.07% year-over-year to 862000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 4539000.0 (changed N/A YoY) and the FY2025 annual result came in at 634000.0, down 12.07% from the prior year.
- Income from Discontinued Operations eased to 862000.0 in Q4 2024, from 804000.0 in the prior quarter.
- In the past five years, Income from Discontinued Operations ranged from a high of 3905000.0 in Q4 2023 to a low of 862000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 25.25 Bn | 25.25 Bn | 1.16 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 373.19 Mn |
| Sep 30, 2024 | -43.08 Mn |
| Jun 30, 2024 | 89.09 Mn |
| Dec 31, 2023 | -227.61 Mn |
| Sep 30, 2023 | -86.48 Mn |